Recent research suggests that GLP-1 medications—initially designed to assist in managing blood sugar levels for those with Type 2 diabetes—may also have beneficial effects in controlling the progression of certain types of cancers linked to obesity. This finding represents a significant development in the understanding of these drugs, which include well-known brands such as Ozempic and Wegovy.
:max_bytes(150000):strip_icc():format(jpeg)/gpl-1-jabs-052226-1-010a064224da4f85bf4c6ea0952739c8.jpg)
The study, conducted by a team led by Dr. Mark David Orland from the Cleveland Clinic’s Taussig Cancer Institute, specifically examined data from over 10,000 cancer patients within the TriNetX Global Health Research Network. The researchers focused on individuals diagnosed with several cancer types, including breast, colorectal, liver, lung, kidney, pancreatic, and prostate cancers. Notably, patients who began taking GLP-1 medications after their cancer diagnosis exhibited a reduced rate of metastatic progression compared to their counterparts on different diabetes medications.
In their findings, the researchers highlighted that, while the trend was observed across multiple cancer types, it was only statistically significant for four: breast, colorectal, liver, and non-small cell lung cancer. This indicates a potential link between the use of GLP-1 drugs and a lower likelihood of cancer spread in those specific cases.
The research also showed promising results for patients suffering from advanced lung cancer. Those with stage 3 lung cancer taking GLP-1 medications were found to be 50% less likely to see their disease progress to stage 4 when compared to patients receiving a class of oral medications known as DPP-4 inhibitors. This group of drugs is another treatment option for Type 2 diabetes that functions by enhancing insulin release post-meal.
Dr. Orland emphasised that the apparent benefits of GLP-1 drugs likely stem from the medications themselves rather than from better overall management of a patient’s diabetes or weight-related issues. Nevertheless, he acknowledged that further clinical trials are essential to establish a clearer causal relationship between GLP-1 use and reduced cancer progression. Currently, the research remains unpublished in a peer-reviewed journal but is scheduled for presentation at an upcoming American Society of Clinical Oncology meeting.
The implications of this study extend beyond cancer treatment. A previous study published in March found that individuals on GLP-1 medications also reported fewer psychiatric issues requiring hospitalisation or extended work absences. This study, which tracked nearly 100,000 individuals in Sweden from 2009 to 2022, included over 20,000 patients using GLP-1 medications. It revealed that during periods on these drugs, people experienced a significant improvement in mental health, suggesting a broader range of benefits associated with GLP-1 treatment.
While the primary purpose of GLP-1 medications has been centred on managing diabetes and aiding weight loss by curbing appetite and enhancing feelings of fullness, the growing body of research is starting to illuminate their potential effects in oncology. As obesity continues to be a crucial risk factor for many cancers, understanding the role that diabetes medications may play in cancer treatment could ultimately lead to new therapeutic strategies.
With the complexities surrounding both diabetes and cancer treatment, these findings are a beacon of hope for patients struggling with cancer linked to obesity. The results could pave the way for more comprehensive approaches to patient care, utilising existing treatments in new and potentially life-saving contexts.
As the medical community continues to explore these possibilities, it remains critical to approach the data with cautious optimism, awaiting further evidence from larger, rigorous clinical trials to substantiate these preliminary findings.